In a phase III clinical trial OlympiAD (NCT02000622) (Study Details Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. This evidence concerns the gene BRCA1 and breast carcinoma.